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TO THE EDITOR
In this journal, Cotter et al. (2007)
recently reported that they cannot
detect Senescence-Associated b-Galac-
tosidase (SA-b-Gal) activity at pH 6 in
human nevi and conclude that nevi do
not exhibit such activity. This is in
contrast with recent reports by our
laboratory and that of D Bennett
(Michaloglou et al., 2005; Gray-Schop-
fer et al., 2006). Here we explain why
the claim put forth by Cotter et al.
is based on a flawed interpretation of
their experimental results. If anything, the
paper by Cotter et al. confirms rather than
refutes our previous report of increased
SA-b-Gal activity in human nevi.
SA-b-Gal activity measured at pH 6
was originally identified by Dimri et al.
(1995) as a senescence biomarker,
because it increases in senescent cells
in vitro as well as in vivo. Since this
publication, literally hundreds of labo-
ratories have used this marker for the
identification of senescence in cells,
in vitro and in vivo. The detection
of SA-b-Gal in nevi by us and Bennett
and co-workers has been paralleled
by many similar findings in other
in vivo lesions, including human
dermal neurofibromas (Courtois-Cox
et al., 2006), human and murine pro-
static adenomas (Chen et al., 2005),
murine lung adenomas, pancreatic in-
traductal neoplasias (Collado et al.,
2005), murine lymphomas (Braig
et al., 2005), and murine melanomas
(Ha et al., 2007).
We agree with the comment made
by Cotter et al. that one should not use
SA-b-Gal activity as the sole marker to
detect senescence. Therefore, to detect
senescence in nevi we have performed,
in addition to SA-b-Gal staining, im-
munohistochemistry for the prolifera-
tion marker Ki-67 as well as the tumor
suppressor p16INK4A (Michaloglou
et al., 2005). In view of their comment,
it is surprising that Cotter et al. neglec-
ted to do this.
Recently, Lee et al. (2006) have
demonstrated that SA-b-Gal corres-
ponds to lysosomal b-Galactosidase
(b-Gal), which is consistent with the
observation that senescent cells increase
lysosome content (Kurz et al., 2000).
Lysosomal b-Gal displays maximal
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Figure 1. b-Gal activity in human nevi at pH range 4–7. (a) Paraffin (15 mm) sections of four samples of the same human nevus stained at pH range 4–7. Pieces
of frozen tissue were fixed and stained for b-Gal activity at pH 4, 5, 6, or 7 in a staining solution containing 5mM K3Fe(CN)6, 5mM K4Fe(CN)6, 2mM MgCl2,
150mM NaCl, 1mg/ml X-gal (in DMF), 40mM citric acid/Na2HPO4, for 16 hours at 371C. The correct pH was confirmed before and after staining. Tissues
were then embedded in paraffin (using isopropanol instead of xylene) and sectioned. Two consecutive sections are shown here, one of which has been
counterstained with hematoxylin and eosin. Bar¼ 200 mm. (b) MelanA immunohistochemical staining of the same nevus as in (a), to indicate the position
of the intradermal nevus cell mass. The figure shows that at pH 6, only nevus cells, but not other cells, including dermal keratinocytes, stain positively for
SA-b-Gal activity. In contrast, at lower pH (4 or 5), global staining for all cell types is observed, consistent with the recent identification that SA-b-Gal
corresponds to lysosomal b-Gal (Lee et al., 2006). Photomicrographs shown here were generated without the help of any imaging software. The evaluation
of specimens was not linked to clinical data at the individual level, and did not in any way influence diagnosis or treatment. According to institutional
guidelines, no patient consent was deemed necessary, and none was sought.
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activity between pH 4 and 4.5, but
markedly lower activity at pH 6. The
increase in lysosomal content of senes-
cent cells favors detection of b-Gal
activity at the suboptimal pH 6 (Lee
et al., 2006, and references therein).
However, even at pH 4, b-Gal staining
differs between normal and senescent
cells.
We have performed b-Gal stainings
at pH 4–7. In agreement with the report
by Lee et al. (2006), we find that at pH
4 and 5, nevus cells show a clear
positive staining, stronger in intensity
than surrounding normal dermal or
epidermal cells (fibroblasts and kerati-
nocytes, respectively; Figure 1). At pH
6, although the total intensity of stain-
ing is reduced, there is a larger differ-
ence between the staining of nevus
cells and the surrounding tissue, as we
previously reported (Michaloglou et al.,
2005). No activity is detected at pH 7.
Of note, and in contrast to the un-
founded allegation by Cotter et al., we
have meticulously controlled the pH
and confirmed it before and after the
staining procedure.
In contrast to their interpretation
and claim, the data of Cotter et al.
support rather than refute our observa-
tions and conclusions. In Figure 1e and
f of their letter, they show nevus
sections stained for b-Gal at pH 6 and
4, respectively. Although the limited
resolution of that figure precludes de-
tailed interpretation, specific staining at
pH 4 is evident in the nevus compart-
ment, with absence of staining in the
adjacent non-neval cells. The only
discrepancy with previous publi-
cations (Michaloglou et al., 2005;
Gray-Schopfer et al., 2006), therefore,
lies at the pH at which b-Gal activity
differences were detected, that is, pH 4
as opposed to pH 6. As it is the same
enzyme that accounts for b-Gal activity
measured at pH 4 and 6, one can
conclude from the results by Cotter
et al. only that, although their detection
of the overall b-Gal activity has been
less sensitive than the one used by us
and many other laboratories, also the
nevi they studied do in fact display
increased activity of this enzyme. The
results by Cotter et al. are thus in
agreement with the literature. The
claim made in their article ‘‘Absence
of senescence-associated b-Gal activity
in human melanocytic nevi in vivo’’ is
unfounded.
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TO THE EDITOR
We appreciate the interest in our letter
(Cotter et al., 2007), which emphasized
two points: (1) that b-gal staining of
nevi (in vivo) at pH 6 is unreliable, and
(2) that it is premature to conclude that
all nevi are senescent. We all agree that
melanocyte senescence, resulting from
oncogene activation or prolonged cul-
ture, is an established phenomenon
in vitro that is associated with positive
b-gal staining at pH 6. Indeed, as shown
in our report, such staining of ‘‘late-
passage’’ melanocytes was quite robust
in our hands. Thus, as a positive control
for our examination of nevi, we em-
bedded late-passage melanocytes in
OCT and prepared frozen sections in a
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